Clinical Trials
17 trialsNCT01286896 2025-07-10
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The Netherlands Cancer Institute
Phase 1 Completed
NCT06940349 2025-04-23
COPS-01
Rabin Medical Center
Phase 1/2 Recruiting
NCT02450123 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02691793 2022-06-15
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase 4 Completed
NCT02058901 2019-07-17
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT00982657 2015-11-20
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT00884676 2015-10-09
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
University of Miami
Phase 1 Completed
NCT00720148 2014-08-26
A Phase I Trial of Bortezomib and Sunitinib
Emory University
Phase 1 Completed
NCT00729833 2014-06-09
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00357318 2014-02-24
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00387920 2014-01-28
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00583063 2013-06-12
Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
University of Chicago
Phase EARLY_PHASE1 Completed
NCT00798889 2013-01-21
Rollover Protocol for Prior SU011248 Protocols
Pfizer
Phase NA Completed
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00528619 2011-04-08
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed